Maharastra, India

Nilesh Sudhir Patil


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Nilesh Sudhir Patil

Introduction

Nilesh Sudhir Patil is a notable inventor based in Maharashtra, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for medical applications. With a total of two patents to his name, Patil's work focuses on innovative solutions for thromboembolic disorders.

Latest Patents

Patil's latest patents include the "Rivaroxaban intermediate and preparation thereof" and the "Aldehyde derivative of substitute oxazolidinones." The first patent relates to a novel intermediate formula for rivaroxaban and outlines a process for its preparation. This involves treating the intermediate with 5-chlorothiophene carbonyl chloride to create rivaroxaban derivatives. The second patent discusses a prodrug of a specific compound, which is aimed at treating thromboembolic disorders. This invention highlights the potential for new therapeutic options in the medical field.

Career Highlights

Nilesh Sudhir Patil is currently employed at Wanbury Limited, where he continues to innovate and develop new pharmaceutical solutions. His work has been instrumental in advancing the company's research and development efforts.

Collaborations

Patil collaborates with talented coworkers, including Nitin Sharadchandra Pradhan and Rajesh Ramchandra Walavalkar. Their combined expertise contributes to the success of their projects and the advancement of their research initiatives.

Conclusion

Nilesh Sudhir Patil's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving medical treatments. His work not only showcases his inventiveness but also highlights the importance of collaboration in achieving significant advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…